In a collaboration between Penn and the Children’s Hospital of Philadelphia, Flavia Vitale, PhD, Assistant Professor of Neurology at Penn, Pedro Gonzalez-Alegre, MD, PhD, former director for clinical programs in the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, and Tim Lucas, formerly at Penn Neurosurgery, jointly invented a multipoint injection technology that improves therapeutic coverage and infusion rate, reduces the number of injections required and minimizes surgical time.
This technology is an intracerebral drug delivery system that consists of three flexible, retractable microcannulas housed within a single central catheter. It can be applied to facilitate the delivery of gene therapies and other fluid-based therapies to different areas of the brain.
PCI is actively seeking partners and investors for further development of this exciting technology opportunity. You can find more information about the technology here.
Multipoint Injection Technology (MINT) is a gene therapy delivery system that includes 3 retractable cannulas within a single catheter to reduce the number of injections required to achieve therapeutic dosage as well as minimize surgical time necessary to deliver therapy.